CDEK
← All organizations

Symbiomix Therapeutics

For profitContributed to NME
Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 3

First clinical trial

May 1, 2014

First marketed drug

Sep 15, 2017

First NDA

Sep 15, 2017

Last known activity

Jun 1, 2015

Acquired by Lupin on Oct 1, 2017

Timeline

2010s

  1. Jul 1, 2012

    Symbiomix Therapeutics— Founded

  2. Sep 15, 2017

    secnidazole— NDA Organization

  3. Oct 1, 2017

    Lupin— Acquired By

Drugs by trial phase (1 distinct, 3 trials)

Phase 3 (1 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (1)

Recent trials (3)

Details

Founded
Newark, TX, US Jul 1, 2012
First NDA
Sep 15, 2017
Last known activity
Jun 1, 2015

Designations held

  • Fast track
  • Priority review

Notes

Acquired by Lupin 11 Oct 2017